Table of Contents Table of Contents 2 List of Tables 3 List of Figures 4 Report Guidance 5 Clinical Trials by Region 6 Clinical Trials and Average Enrollment by Country 7 Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10 Top Five Countries Contributing to Clinical Trials in Europe 11 Top Countries Contributing to Clinical Trials in North America 12 Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13 Top Countries Contributing to Clinical Trials in Central and South America 14 Clinical Trials by G7 Countries: Proportion of Ankylosing Spondylitis (Bekhterev's Disease) to Musculoskeletal Disorders Clinical Trials 15 Clinical Trials by Phase in G7 Countries 17 Clinical Trials in G7 Countries by Trial Status 18 Clinical Trials by E7 Countries: Proportion of Ankylosing Spondylitis (Bekhterev's Disease) to Musculoskeletal Disorders Clinical Trials 19 Clinical Trials by Phase in E7 Countries 21 Clinical Trials in E7 Countries by Trial Status 22 Clinical Trials by Phase 23 In Progress Trials by Phase 24 Clinical Trials by Trial Status 25 Clinical Trials by End Point Status 26 Subjects Recruited Over a Period of Time 27 Clinical Trials by Sponsor Type 28 Prominent Sponsors 29 Top Companies Participating in Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials 30 Prominent Drugs 32 Latest Clinical Trials News on Ankylosing Spondylitis (Bekhterev's Disease) 33 Mar 18, 2016: Celltrion Healthcare: Switching to Remsima (infliximab) from originator has no negative effect on safety or efficacy in 10 real-world studies 33 Mar 16, 2016: Significantly higher persistence with SIMPONI (golimumab) in patients with rheumatic diseases compared with other subcutaneous TNF-alpha inhibitors, new study reveals 34 Clinical Trial Profile Snapshots 35 Appendix 216 Abbreviations 216 Definitions 216 Research Methodology 217 Secondary Research 217 About GlobalData 218 Contact Us 218 Disclaimer 218 Source 219

List of Tables Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, Global, Clinical Trials by Region, 2016* 6 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 10 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials, North America, Top Countries, 2016* 12 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 13 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 14 Proportion of Ankylosing Spondylitis (Bekhterev's Disease) to Musculoskeletal Disorders Clinical Trials, G7 Countries (%), 2016* 16 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 17 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 18 Proportion of Ankylosing Spondylitis (Bekhterev's Disease) to Musculoskeletal Disorders Clinical Trials, E7 Countries (%), 2016* 20 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 21 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 22 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, Global, Clinical Trials by Phase, 2016* 23 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 24 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 25 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 26 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 27 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 28 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 29 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 31 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 32 List of Figures Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, Global, Clinical Trials by Region (%), 2016* 6 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 10 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 13 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 14 Proportion of Ankylosing Spondylitis (Bekhterev's Disease) to Musculoskeletal Disorders Clinical Trials, G7 Countries (%), 2016* 15 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 17 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 18 Proportion of Ankylosing Spondylitis (Bekhterev's Disease) to Musculoskeletal Disorders Clinical Trials, E7 Countries (%), 2016* 19 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 21 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 22 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, Global, Clinical Trials by Phase (%), 2016* 23 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 24 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 25 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 26 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 27 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 28 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 29 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 30 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 32 GlobalData Methodology 217

Pfizer Inc. AbbVie Inc. Johnson & Johnson Merck & Co., Inc. C. H. Boehringer Sohn AG & Co. KG Novartis AG UCB S.A. Parexel International Corporation Celgene Corporation Amgen Inc.